1. Home
  2. FATE vs ASPS Comparison

FATE vs ASPS Comparison

Compare FATE & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • ASPS
  • Stock Information
  • Founded
  • FATE 2007
  • ASPS 1999
  • Country
  • FATE United States
  • ASPS Luxembourg
  • Employees
  • FATE N/A
  • ASPS N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • ASPS Other Consumer Services
  • Sector
  • FATE Health Care
  • ASPS Consumer Discretionary
  • Exchange
  • FATE Nasdaq
  • ASPS Nasdaq
  • Market Cap
  • FATE 116.5M
  • ASPS 104.5M
  • IPO Year
  • FATE 2013
  • ASPS N/A
  • Fundamental
  • Price
  • FATE $1.06
  • ASPS $9.84
  • Analyst Decision
  • FATE Buy
  • ASPS
  • Analyst Count
  • FATE 7
  • ASPS 0
  • Target Price
  • FATE $3.92
  • ASPS N/A
  • AVG Volume (30 Days)
  • FATE 2.1M
  • ASPS 18.5K
  • Earning Date
  • FATE 11-12-2025
  • ASPS 10-23-2025
  • Dividend Yield
  • FATE N/A
  • ASPS N/A
  • EPS Growth
  • FATE N/A
  • ASPS N/A
  • EPS
  • FATE N/A
  • ASPS 0.00
  • Revenue
  • FATE $8,470,000.00
  • ASPS $169,648,000.00
  • Revenue This Year
  • FATE N/A
  • ASPS $38.29
  • Revenue Next Year
  • FATE N/A
  • ASPS N/A
  • P/E Ratio
  • FATE N/A
  • ASPS $1,480.14
  • Revenue Growth
  • FATE N/A
  • ASPS 10.68
  • 52 Week Low
  • FATE $0.66
  • ASPS $3.46
  • 52 Week High
  • FATE $3.50
  • ASPS $15.96
  • Technical
  • Relative Strength Index (RSI)
  • FATE 37.34
  • ASPS 42.78
  • Support Level
  • FATE $1.00
  • ASPS $9.21
  • Resistance Level
  • FATE $1.51
  • ASPS $10.38
  • Average True Range (ATR)
  • FATE 0.15
  • ASPS 0.70
  • MACD
  • FATE -0.05
  • ASPS 0.04
  • Stochastic Oscillator
  • FATE 6.38
  • ASPS 33.81

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About ASPS Altisource Portfolio Solutions S.A.

Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.

Share on Social Networks: